VERU | Veru Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6114 - 0.6400
52 Week Range	0.3600 - 1.9200
Beta	-0.30
Implied Volatility	302.54%
IV Rank	23.29%
Day's Volume	597,344
Average Volume	689,378
Shares Outstanding	146,384,000
Market Cap	91,533,915
Sector	Healthcare
Industry	Biotechnology
IPO Date	1999-02-11

Valuation
Profitability
Growth
Health
P/E Ratio	-2.08
Forward P/E Ratio	-22.23
EPS	-0.30
1YR Price Target	31.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	189
Country	USA
Website	VERU

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.

VERU's peers: MCRB, PLX, LXRX, IOVA, IMGN, TSVT, ICPT, PBYI, SRPT, AVXL, ANVS, AXSM, NVAX

*Chart delayed

Analyzing fundamentals for VERU we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see VERU Fundamentals page.

Watching at VERU technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VERU Technicals page.